Sublingual immunotherapy tablet for the treatment of house dust mite allergic rhinitis in Canada: an alternative to minimize treatment costs?

Allergy, Asthma & Clinical Immunology
• Research
• Open Access

• Anne K. Ellis,
• Rémi Gagnon,
• Eva HammerbyEmail authorView ORCID ID profile and
• Andrea Lau

Allergy, Asthma & Clinical Immunology201915:27

https://doi.org/10.1186/s13223-019-0344-3

Abstract

Background

A cost-minimization analysis (CMA) was performed to estimate the economic impact of introducing the SQ house dust mite sublingual immunotherapy (SQ HDM SLIT)-tablet marketed as ACARIZAX™ (regulatory approval May 2017) for the treatment of HDM-induced allergic rhinitis in Canada (Ontario and Quebec), where house dust mite subcutaneous immunotherapy (HDM SCIT) is already an available treatment option.

Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis

ORIGINAL RESEARCH

          

• Abstract
• Fulltext
• Metrics
• Get Permission

Authors Tang B, Wang J, Luo LL, Li QG, Huang D

Received 25 October 2018

Accepted for publication 12 February 2019

Published 1 April 2019 Volume 2019:14 Pages 757—766

DOI https://doi.org/10.2147/COPD.S192166

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Justinn Cochran

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Chunxue Bai

Bin Tang,¹ Jun Wang,¹ Lin-lin Luo,¹ Qiu-gen Li,^1,* Dan Huang<sup>2,*

1</sup>Department of Respiratory Medicine, Jiangxi Provincial People’s Hospital Affiliated to Nanchang University, No. 92 Aiguo Road, Nanchang, 330006, Jiangxi, China; ²Department of Anesthesiology, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Nanchang, 330006, Jiangxi, China

^*These authors contributed equally to this work
Purpose: The aim of this study was to investigate the comparative risks of budesonide/formoterol, versus placebo or monotherapies, for the treatment of patients with stable COPD.

Unmet needs in asthma

• Journal List
• Ther Clin Risk Manag
• v.15; 2019
• PMC6422410

Ther Clin Risk Manag. 2019; 15: 409–421.

Published online 2019 Mar 14. doi: 10.2147/TCRM.S160327

PMCID: PMC6422410

PMID: 30936704

Kevin Gruffydd-Jones

Abstract

Despite advances in the diagnosis and management of asthma, uncontrolled disease is still associated with a substantial mortality and morbidity burden. Patients often overestimate their level of asthma control while also reporting that asthma symptoms affect their quality of life and ability to work or study.

Allergic reactions after vaccination: translating guidelines into clinical practice

A. Radice¹radiceanna87@gmail.com, G. Carli², D. Macchia¹, A. Farsi²   

Show more: Authors information and Publication history

Doihttps://doi.org/10.23822/EurAnnACI.1764-1489.86

SummaryVaccination represents one of the most powerful medical interventions on global health.

Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019

Allergology International

Available online 16 April 2019

open access

In Press, Corrected ProofWhat are Corrected Proof articles?

Invited Review Article

Author links open overlay panelTetsuoShioharaYoshikoMizukawa

https://doi.org/10.1016/j.alit.2019.03.006Get rights and content

Under a Creative Commons license

Abstract

The aim of this review was to provide an updated overview of drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS).

What vaccines are safe for breastfeeding women?

The research reviewed all of the most common types of vaccines, including inactivated and live attenuated types, for the 'unsubstantiated concern' that they would cause harm to a nursing infant or interfere with the infant’s response to early childhood vaccinations. 

It confirmed that no routine vaccines are contraindicated in nursing mothers. However, it says that yellow fever vaccine should not be given to mothers who are breastfeeding an infant younger than nine months of age unless it is absolutely unavoidable. Meanwhile, smallpox vaccine should not be given to nursing mothers, while adenovirus type 4 and type 7 vaccine is also not recommended. 

In an accompanying editorial , Dr Arthur I. Eidelman, Editor-in-Chief of Breastfeeding Medicine said not only is there no harm in administering routine vaccinations to breastfeeding mothers, but there are benefits for both the mothers and infants, including the transfer of maternal antibodies to the infant and an enhanced antibody response. 

Philip O. Anderson. Maternal Vaccination and Breastfeeding

Breastfeeding Medicine.http://doi.org/10.1089/bfm.2019.0045 Open Access

• Online Ahead of Print:March 19, 2019
• PDF

The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option

• 
  Email authorLeif Bjermer

Allergy, Asthma & Clinical Immunology201915:24

https://doi.org/10.1186/s13223-018-0314-1 

Leif Bjermer, Marit Westman, Mats Holmström and Magnus C. Wickman

Abstract

Allergic rhinitis (AR) poses a global health problem and can be challenging to treat. Many of the current symptomatic treatments for AR have been available for decades, yet there has been little improvement in patient quality of life or symptom burden over the years.

The alpha-Gal syndrome: new insights into the tick-host conflict and cooperation

Parasites & Vectors


• Primer
• Open Access

• José de la FuenteEmail author,
• Iván Pacheco,
• Margarita Villar and
• Alejandro Cabezas-Cruz

Parasites & Vectors201912:154

https://doi.org/10.1186/s13071-019-3413-z

Abstract

This primer focuses on a recently diagnosed tick-borne allergic disease known as the alpha-Gal syndrome (AGS). Tick bites induce in humans high levels of IgE antibodies against the carbohydrate Galα1-3Galβ1-(3)4GlcNAc-R (α-Gal) present on tick salivary glycoproteins and tissues of non-catarrhine mammals, leading to the AGS in some individuals. This immune response evolved as a conflict and cooperation between ticks and human hosts including their gut microbiota.

An Epinephrine Prefilled Syringe (Symjepi) for Anaphylaxis

Download PDF:   US English

   

Show Related
Terms

View Complete Issue

Send Article Feedback

February 25, 2019 (Issue: 1566)

The FDA has approved a manually injected, single-dose, prefilled epinephrine syringe (Symjepi – Adamis/Sandoz) for emergency treatment of anaphylaxis. The new device is approved in 0.3- and 0.15-mg strengths for treatment of patients weighing ≥30 kg and 15 to 30 kg, respectively; only the 0.3-mg strength is currently available. According to Sandoz, Symjepi will be made available first to institutions and later to the retail market.

EPINEPHRINE AUTO-INJECTORS — EpiPen and EpiPen Jr, which are also available generically, have been used effectively for treatment of anaphylaxis for many years (see Table 1). A generic version of the Adrenaclick auto-injector (no longer manufactured) is also available; it is similar to EpiPenin size and functionality. Auvi-Q, which is the size of a thick credit card, provides visual signals and audio instructions, has an automatic needle retraction system, and appears to be more convenient to carry and easier to use than EpiPen.1 It is the only auto-injector available in a 0.1-mg strength for use in children weighing 7.5-15 kg.2 Because of differences in device design and instructions for use, these 3 auto-injectors are not considered interchangeable, and pharmacists cannot substitute one for another.

Anaphylactic shock due to patent blue: case report and review of literature

Pan Afr Med J. 2018; 31: 7.

Asma Korbi,1,& Amel Khaskhoussy,1 Ons Cherif,1 Ahmed Hajji,1 Imen Gaddab,1 Amel Chaabene,2 Mouna Gara,3 Fathi Jbeli,3 Lotfi Grati,3 Med Salah Rhim,1 and Raja Faleha1

Go to:

Abstract

Go to:

Abstract

Abstract

Intraoperative search for the sentinal node using patent blue is considered a non risk procedure. We emphasize the highly exceptional nature of this adverse effect previously observed in other disciplines using this coloring agent. 

We present a case of allergic reaction to patent blue in a patient who underwent left mastectomy with sentinel lymph node.

Comparison of bench test results measuring the accuracy of peak flow meters

BMC Pulmonary Medicine  RESEARCH ARTICLE

Cristiano VanZeller, Andrew Williams and Ian Pollock

BMC Pulmonary Medicine 2019, 19:74  Abstract Background The study evaluates and compares the accuracy of nine peak flow meters (“PFMs”) and spirometers that are currently available in Europe and have Conformité Européene (“CE”) marking. The CE marking is a manufacturer’s declaration that their product complies with European health regulations and it is a requirement for marketing medical devices in Europe.

Does transbronchial lung cryobiopsy give useful information in asthmatic patients?

Multidisciplinary Respiratory Medicine ORIGINAL RESEARCH ARTICLE

Sara Colella, Claudia Ravaglia, Chiara Massaccesi, Vittorio D’Emilio, Gianluca Panella, Federica Fioretti, Emanuele Giovanni Conte, Guido Collina, Riccardo Pela and Venerino Poletti

Multidisciplinary Respiratory Medicine 2019, 14:12

Abstract Introduction Lung biopsy in asthmatic patients is justified in case of atypical presentations of asthma, when other differential diagnoses, such as hypersensitivity pneumonitis or eosinophilic granulomatosis with polyangiitis, could be possible or for research purposes.

Allergy, Asthma & Clinical Immunology

Volume 15 Supplement 2

AllerGen’s 9th Research Conference

• Meeting Abstracts
• Open Access

Proceedings of AllerGen 2019 Research Conference

Allergy, Asthma & Clinical Immunology201915 (Suppl 2) :17

https://doi.org/10.1186/s13223-019-0330-9

Download PDF

Triamcinolone Acetonide versus Fluticasone Propionate in the Treatment of Perennial Allergic Rhinitis: A Randomized, Parallel-Group Trial

Int Arch Allergy Immunol. 2019 Mar 15:1-10. doi: 10.1159/000497160. [Epub ahead of print] 
Karaulov AV, Vylegzhanina T, Ovchinnikov A, Chernikova M, Nenasheva N.

Abstract

BACKGROUND: Intranasal sprays are recommended as targeted therapy for allergic rhinitis (AR). Triamcinolone acetonide is a nasal corticosteroid preparation indicated for the treatment of seasonal and perennial AR (PAR) in different countries worldwide.